DAIICHI SANKYO, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 19
- Registration Number
- NCT01390337
- Locations
- 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸M.D. Anderson Cancer Center, Houston, Texas, United States
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2014-02-25
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 42
- Registration Number
- NCT01364844
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma
- First Posted Date
- 2011-05-06
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 38
- Registration Number
- NCT01349036
- Locations
- 🇺🇸
University California, Los Angeles, Los Angeles, California, United States
🇺🇸University California, San Francisco, San Francisco, California, United States
🇺🇸Dana Faber Cancer Institute, Boston, Massachusetts, United States
Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- First Posted Date
- 2011-05-06
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 90
- Registration Number
- NCT01349049
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
- Conditions
- Interventions
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 36
- Registration Number
- NCT01290471
- Locations
- 🇺🇸
Univ. Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States
🇺🇸Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
A Study of DS-2248 in Participants With Advanced Solid Tumors
- First Posted Date
- 2011-02-02
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 60
- Registration Number
- NCT01288430
Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects
- First Posted Date
- 2011-02-02
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 88
- Registration Number
- NCT01287858
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease
- First Posted Date
- 2010-12-15
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 110
- Registration Number
- NCT01260584
- Locations
- 🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
🇺🇸The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital, Cincinnati, Ohio, United States
🇺🇸Sanai Center for Thrombosis Research, Baltimore, Maryland, United States
Colesevelam for Children With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2010-12-10
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 236
- Registration Number
- NCT01258075
Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Daiichi Sankyo
- Registration Number
- NCT01245543
- Locations
- 🇺🇸
University of California San Francisco (UCSF), San Francisco, California, United States
🇺🇸South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States